SCHEMBL1992386

SCHEMBL1992386

O=C(O)[C@H]1COCCN1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL40204 1.00
SCHEMBL40203 1.00
Bromide SCHEMBL28064331 0.98 CYP2D6 (0.37)
Hydrochloric Acid SCHEMBL28233359 0.98 CYP2D6 (0.37)
Hydrochloric Acid SCHEMBL2075067 0.98 CYP2D6 (0.37)
Hydrochloric Acid SCHEMBL17874011 0.98 CYP2D6 (0.37)
Sulfuric Acid SCHEMBL28240058 0.92 CYP2D6 (0.33)
Alcohol SCHEMBL28206180 0.90 CTSC (0.34)
SCHEMBL18555392 0.87 BLM (0.36)
SCHEMBL29954373 0.87 BLM (0.36)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170260178-A1 ANTIBACTERIAL COMPOUNDS SPERO GYRASE INC (US) 2017-09-14 US claimed
EP-2828257-B1 ANTIBACTERIAL COMPOUNDS BIOTA EUROPE LTD (GB) 2017-07-26 EP claimed
EP-2828257-A1 ANTIBACTERIAL COMPOUNDS Biota Europe Ltd (GB) 2015-01-28 EP claimed
WO-2013138860-A1 ANTIBACTERIAL COMPOUNDS BIOTA EUROPE LIMITED (GB) 2013-09-26 WO claimed
WO-2025080946-A2 RAS INHIBITORS Revolution Medicines, Inc. (US) 2025-04-17 WO disclosed
US-20240376099-A1 COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF ENDOSOMAL TOLL-LIKE RECEPTORS NOVARTIS AG (CH) 2024-11-14 US disclosed
EP-3998260-B1 SGC STIMULATORS CYCLERION THERAPEUTICS INC (US) 2023-11-01 EP disclosed
EP-3684776-B1 HETEROCYCLYL SUBSTITUTED PYRROLOPYRIDINES THAT ARE INHIBITORS OF THE CDK12 KINASE UNIV NOTTINGHAM (GB) 2023-11-01 EP disclosed
EP-3253752-B1 [9,10-DIMETHOXY-3-(2-METHYLPROPYL)-1H,2H,3H,4H,6H,7H,11BH-PYRIDO-[2,1-A]ISOQUINOLIN-2-YL]METHANOL AND COMPOUNDS, COMPOSITIONS AND METHODS RELATING THERETO NEUROCRINE BIOSCIENCES INC (US) 2023-08-16 EP disclosed
CN-111601798-B Bisamide sarcomere activating compounds and uses thereof 美国安进公司 2023-08-11 CN disclosed
CN-109369635-B Compound or pharmaceutically acceptable salt thereof, application thereof and pharmaceutical composition 赛克里翁治疗有限公司 2023-06-30 CN disclosed
WO-2023067353-A1 HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER ARTIOS PHARMA LIMITED (GB) 2023-04-27 WO disclosed
WO-2011075565-A1 SUBSTITUTED AMINOTHIAZOLONE INDAZOLES AS ESTROGEN RELATED RECEPTOR-Aα MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2011-06-23 WO disclosed
US-20110150864-A1 SUBSTITUTED AMINOTHIAZOLONE INDAZOLES AS ESTROGEN RELATED RECEPTOR-ALPHA MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2011-06-23 US disclosed
US-7731949-B2 2010-06-08 US disclosed
WO-2009120652-A2 MONOCYCLIC CGRP RECEPTOR ANTAGONISTS MERCK & CO., INC. (US) 2009-10-01 WO disclosed
EP-2076264-A2 COMPOUNDS AND METHODS FOR TREATMENT OF HCV XTL Biopharmaceuticals LTD (US) 2009-07-08 EP disclosed
US-20090041723-A1 Compounds and methods for treatment of HCV XTL BIOPHARMACEUTICALS LTD. (IL) 2009-02-12 US disclosed
JP-2008297269-A METHOD FOR PRODUCING (R)-3-MORPHOLINECARBOXYLIC ACID HOKKO CHEM IND CO LTD 2008-12-11 JP disclosed
WO-2008048589-A2 COMPOUNDS AND METHODS FOR TREATMENT OF HCV XTL BIOPHARMACEUTICALS LTD (US) 2008-04-24 WO disclosed